An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cue Health to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cue Health (Nasdaq: HLTH), a leader in healthcare technology, announced management presentations at two major investor conferences. The Cowen 42nd Annual Health Care Conference will take place on March 8, 2022 at 1:30 p.m. Eastern Time. The following day, Morgan Stanley Technology, Media & Telecom Conference will occur on March 9, 2022 at 4:15 p.m. Eastern Time in San Francisco. Interested investors can access the live webcasts and 90-day replays on Cue's website.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the following upcoming investor conferences:
Cowen 42nd Annual Health Care Conference Presenting on Tuesday, March 8, 2022 at 1:30 p.m. Eastern Time
Morgan Stanley Technology, Media & Telecom Conference Presenting on Wednesday, March 9, 2022 at 4:15 p.m. Eastern Time at The Palace Hotel in San Francisco
The live webcasts and replays of the presentations may be accessed for 90 days on the “Investor Relations” section of the company’s website at: www.cuehealth.com.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care. Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India'sCentral Drugs Standard Control Organization, and PSAR authorization from Singapore’s Health Sciences Authority. Cue was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
